摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

罗库溴胺 | 143558-00-3

中文名称
罗库溴胺
中文别名
——
英文名称
Rocuronium
英文别名
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
罗库溴胺化学式
CAS
143558-00-3
化学式
C32H53N2O4+
mdl
——
分子量
529.8
InChiKey
YXRDKMPIGHSVRX-OOJCLDBCSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    溶于二甲基亚砜
  • 物理描述:
    Solid

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    38
  • 可旋转键数:
    6
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.91
  • 拓扑面积:
    59
  • 氢给体数:
    1
  • 氢受体数:
    5

ADMET

代谢
罗库溴铵被代谢为活性较低的代谢物,17-脱乙酰罗库溴铵,主要通过肝脏消除。
Rocuronium is metabolized to a less active metabolite, 17-desacetyl-rocuronium, and is eliminated primarily by the liver.
来源:DrugBank
毒理性
  • 药物性肝损伤
化合物:罗库溴铵
Compound:rocuronium
来源:Drug Induced Liver Injury Rank (DILIrank) Dataset
毒理性
  • 药物性肝损伤
DILI 注释:无 DILI(药物性肝损伤)担忧
DILI Annotation:No-DILI-Concern
来源:Drug Induced Liver Injury Rank (DILIrank) Dataset
毒理性
  • 药物性肝损伤
标签部分:无匹配
Label Section:No match
来源:Drug Induced Liver Injury Rank (DILIrank) Dataset
毒理性
  • 药物性肝损伤
参考文献:M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. 美国食品药品监督管理局批准的药物标签用于研究药物诱导的肝损伤,《药物发现今日》,16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007 M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank:按人类发展药物诱导肝损伤风险排名的最大参考药物清单。《药物发现今日》2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015
References:M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007 M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015
来源:Drug Induced Liver Injury Rank (DILIrank) Dataset
毒理性
  • 在妊娠和哺乳期间的影响
◉ 母乳喂养期间使用总结:关于母乳喂养期间使用维库溴铵的信息有限,表明对婴儿没有不良影响。由于它作用时间短,极性高,口服吸收不良,因此不太可能以高浓度进入母乳或进入婴儿的血液循环。当使用多种麻醉剂组合进行手术时,请遵循手术期间使用的最有问题的药物的建议。以维库溴铵为组成部分的剖宫产全身麻醉可能会延迟泌乳的开始。 ◉ 对哺乳婴儿的影响:四名正在哺乳3至5个月大婴儿的母亲在接受全身麻醉时,给予了静脉注射丙泊酚瑞芬太尼作为诱导剂,以及0.5 mg/kg的维库溴铵用于插管。诱导后,停止丙泊酚,并使用氙气吸入来维持麻醉,持续57至70分钟。婴儿在手术结束后的1.5至5小时内恢复哺乳。没有婴儿出现明显的头晕或嗜睡症状。所有婴儿在母亲出院后的家中都表现良好,没有注意到任何不良事件。 ◉ 对泌乳和母乳的影响:一项随机研究比较了使用全身麻醉、脊髓麻醉或硬脊膜外麻醉进行剖宫产与正常阴道分娩对血清催乳素催产素的影响以及开始泌乳的时间。全身麻醉使用丙泊酚2 mg/kg和维库溴铵0.6 mg/kg进行诱导,随后根据需要使用七醚和维库溴铵0.15 mg/kg。分娩后,所有组的患者接受了1 L盐中的催产素30国际单位输注,如果他们没有高血压,则额外给予0.2 mg的甲基麦角新碱。全身麻醉组在分娩后给予了1至1.5 mcg/kg的芬太尼。全身麻醉组(n = 21)的术后催乳素平较高,开始泌乳的平均时间(25小时)比其他组(10.8至11.8小时)长。非药物阴道分娩组产后的催产素平高于全身和脊髓麻醉组。
◉ Summary of Use during Lactation:Limited information on the use of rocuronium during breastfeeding indicates that no adverse infant effects occur. Because it is short acting, highly polar and poorly absorbed orally, it is not likely to reach the breastmilk in high concentration or to reach the bloodstream of the infant. When a combination of anesthetic agents is used for a procedure, follow the recommendations for the most problematic medication used during the procedure. General anesthesia for cesarean section using rocuronium as a component may delay the onset of lactation. ◉ Effects in Breastfed Infants:Four mothers who were breastfeeding 3- to 5-month-old infants underwent general anesthesia were given intravenous propofol and remifentanil as induction agents and rocuronium 0.5 mg/kg for intubation. After induction, propofol was stopped and xenon inhalation was used to maintain anesthesia for between 57 and 70 minutes. Infants resumed breastfeeding from 1.5 to 5 hours after the end of surgery. None of the infants had noticeable symptoms of dizziness or drowsiness. All infants fared well at home after their mothers were discharged with no adverse events noticed at home. ◉ Effects on Lactation and Breastmilk:A randomized study compared the effects of cesarean section using general anesthesia, spinal anesthesia, or epidural anesthesia, to normal vaginal delivery on serum prolactin and oxytocin as well as time to initiation of lactation. General anesthesia was performed using propofol 2 mg/kg and rocuronium 0.6 mg/kg for induction, followed by sevoflurane and rocuronium 0.15 mg/kg as needed. After delivery, patients in all groups received an infusion of oxytocin 30 international units in 1 L of saline, and 0.2 mg of methylergonovine if they were not hypertensive. Fentanyl 1 to 1.5 mcg/kg was administered after delivery to the general anesthesia group. Patients in the general anesthesia group (n = 21) had higher post-procedure prolactin levels and a longer mean time to lactation initiation (25 hours) than in the other groups (10.8 to 11.8 hours). Postpartum oxytocin levels in the nonmedicated vaginal delivery group were higher than in the general and spinal anesthesia groups.
来源:Drugs and Lactation Database (LactMed)
吸收、分配和排泄
  • 吸收
从胃肠道吸收不良。
Poorly absorbed from the GI tract.
来源:DrugBank
吸收、分配和排泄
  • 消除途径
在猫和狗中关于分布、代谢和排泄的研究表明,罗库溴铵主要通过肝脏消除。
Studies of distribution, metabolism, and excretion in cats and dogs indicate that rocuronium is eliminated primarily by the liver.
来源:DrugBank
吸收、分配和排泄
  • 分布容积
0.3 L/kg [3至<12个月] 0.26 L/kg [1至<3岁] 0.21 L/kg [3至<8岁]
0.3 L/kg [3 to <12 mos] 0.26 L/kg [1 to <3 yrs] 0.21 L/kg [3 to <8 yrs]
来源:DrugBank
吸收、分配和排泄
  • 清除
0.25 升/千克/小时 [成年人(27至58岁)] 0.21 升/千克/小时 [老年人(65岁及以上)] 0.16 升/千克/小时 [正常肝肾功能] 0.13 升/千克/小时 [肾移植患者] 0.13 升/千克/小时 [肝功能不全患者] 0.35 +/- 0.08 升/千克/小时 [儿科患者 3至<12个月] 0.32 +/- 0.07 升/千克/小时 [儿科患者 1至3岁] 0.44 +/- 0.16 升/千克/小时 [儿科患者 3至8岁]
0.25 L/kg/hr [Adults (Ages 27 to 58 years)] 0.21 L/kg/hr [Geriatrics (>=65 yrs)] 0.16 L/kg/hr [Normal ewnal and hepatice function] 0.13 L/kg/hr [Renal transplant patients] 0.13 L/kg/hr [Hepatic dysfunction patients] 0.35 +/- 0.08 L/kg/hr [Pediatric Patients 3 to <12 mos] 0.32 +/- 0.07 L/kg/hr [Pediatric Patients 1 to 3 yrs] 0.44 +/- 0.16 L/kg/hr [Pediatric Patients 3 to 8 yrs]
来源:DrugBank

制备方法与用途

生物活性方面,罗库溴铵(Org-9426)是一种基甾体类非去极化型神经肌肉阻断剂或肌肉松弛剂。

反应信息

  • 作为反应物:
    描述:
    罗库溴胺3-溴丙烯二氯甲烷 为溶剂, 生成 罗库溴铵
    参考文献:
    名称:
    Purification process comprising dissolving an organic compound in carbonated water and freeze-drying
    摘要:
    一种用于精制粗有机化合物的过程,包括将该化合物溶解在碳酸水中形成溶液,并将该溶液冷冻干燥。
    公开号:
    US08242265B2
  • 作为产物:
    描述:
    (5S,8R,9S,10S,13S,14S)-10,13-dimethyltetradecahydrospiro[cyclopenta[a]phenanthrene-17,2'-[1,3]dioxolan]-3(2H)-one 以97的产率得到罗库溴胺
    参考文献:
    名称:
    制备表雄酮的方法
    摘要:
    本发明公开了一种制备表雄酮的方法,以4-雄烯二酮(Ⅰ)为原料,制备得到表雄酮,反应式如下:。本发明首次以价格低廉的4-雄烯二酮为原料,以温和的反应条件合成了表雄酮,极大地降低了生产成本,适合规模化工业生产。
    公开号:
    CN105503985A
点击查看最新优质反应信息

文献信息

  • [EN] PROCESS FOR PREPARATION OF HIGHLY PURE 3-DIMETHYLAMINOPHENYL DIMETHYLCARBAMATE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DIMÉTHYLCARBAMATE DE 3-DIMÉTHYLAMINOPHÉNYLE HAUTEMENT PUR
    申请人:NEON LAB LTD
    公开号:WO2012131699A1
    公开(公告)日:2012-10-04
    The invention discloses a novel process for preparation of highly pure 3-dimethylaminophenyl dimethylcarbamate via formation of aryl dimethylcarbamate which can be easily obtained from diaryl carbonate and dimethylamine.
    该发明揭示了一种新的制备高纯度3-二甲基基苯基二甲基氨基甲酸酯的方法,通过生成芳基二甲基氨基甲酸酯,该芳基二甲基氨基甲酸酯可以很容易地从二芳基碳酸酯和二甲胺中获得。
  • DICATION COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF
    申请人:WEST CHINA HOSPITAL, SICHUAN UNIVERSITY
    公开号:US20210214304A1
    公开(公告)日:2021-07-15
    A dication compound represented by formula (I), stereoisomers having the structure of formula (I) or a mixture of the stereoisomers, a pharmaceutically acceptable salt, a solvate, or a eutectic crystal, and a composition thereof, and use of a composition, are capable of producing neuromuscular junction retardation, formed of same with a pharmaceutically acceptable carrier in the field of preparation of a medicament for muscular flaccidity.
    由式(I)表示的二聚化合物,具有式(I)结构的立体异构体或立体异构体的混合物,药学上可接受的盐,溶剂合物或共晶晶体,以及其组合物,以及组合物的使用,能够在制备用于肌肉松弛症的药物领域中与药学上可接受的载体一起形成神经肌肉接头延迟。
  • MULTIFUNCTIONAL SMALL MOLECULES
    申请人:Baker, JR. James R.
    公开号:US20120259114A1
    公开(公告)日:2012-10-11
    The present invention relates to dendrimer synthesis. Specifically, the present invention relates to triazine scaffolds capable of click chemistry for one-step synthesis of functionalized dendrimers, and methods of making and using the same.
    本发明涉及树枝状大分子的合成。具体而言,本发明涉及能够进行点击化学的 三嗪支架,用于一步法合成功能化树枝状大分子,以及制造和使用该支架的方法。
  • [EN] PHARMACEUTICAL COMPOSITIONS OF POLYANIONIC AND NON-IONIC CYCLODEXTRIN-BASED DENDRIMERS AND USES THEREOF<br/>[FR] COMPOSITIONS PHARMACEUTIQUES DE DENDRIMÈRES À BASE DE CYCLODEXTRINE POLYANIONIQUE ET NON-IONIQUE ET UTILISATIONS ASSOCIÉES
    申请人:LING CHANG-CHUN
    公开号:WO2016161501A1
    公开(公告)日:2016-10-13
    The present application provides pharmaceutical compositions comprising polyanionic and polynon-ionic cyclodextrin-based dendrimers. The compositions can be used as excipients, or to bind to compounds such as in the use as a rescue medicine to remove undesired drugs and metabolites from a subject. Methods of use in treating a subject are also provided.
    当前申请提供了包含多阴离子和多非离子环糊精基树枝状聚合物的药物组合物。这些组合物可以用作辅料,或者用于结合化合物,例如用作救援药物以从主体中去除不需要的药物和代谢物。还提供了用于治疗主体的方法。
  • [EN] BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS<br/>[FR] PRO-FRAGMENTS BIORÉVERSIBLES POUR MÉDICAMENTS CONTENANT DE L'AZOTE ET DE L'HYDROXYLE
    申请人:BAIKANG SUZHOU CO LTD
    公开号:WO2015081891A1
    公开(公告)日:2015-06-11
    Disclosed are promoieties of the following formula which can be used to form prodrugs of nitrogen-containing or hydroxyl-containing drug or a pharmaceutically active agent: (I) and pharmaceutical compositions comprising the prodrugs.
    披露了以下公式的促销性质,它们可用于形成含有氮或羟基的药物或药物活性剂的的前药:(I)以及包含这些前药的药物组合物。
查看更多

同类化合物

(5β)-17,20:20,21-双[亚甲基双(氧基)]孕烷-3-酮 (5α)-2′H-雄甾-2-烯并[3,2-c]吡唑-17-酮 (3β,20S)-4,4,20-三甲基-21-[[[三(异丙基)甲硅烷基]氧基]-孕烷-5-烯-3-醇-d6 (25S)-δ7-大发酸 (20R)-孕烯-4-烯-3,17,20-三醇 (11β,17β)-11-[4-({5-[(4,4,5,5,5-五氟戊基)磺酰基]戊基}氧基)苯基]雌二醇-1,3,5(10)-三烯-3,17-二醇 齐墩果酸衍生物1 黄麻属甙 黄芪皂苷III 黄芪皂苷 II 黄芪甲苷 IV 黄芪甲苷 黄肉楠碱 黄果茄甾醇 黄杨醇碱E 黄姜A 黄夹苷B 黄夹苷 黄夹次甙乙 黄夹次甙乙 黄夹次甙丙 黄体酮环20-(乙烯缩醛) 黄体酮杂质EPL 黄体酮杂质1 黄体酮杂质 黄体酮杂质 黄体酮EP杂质M 黄体酮EP杂质G(RRT≈2.53) 黄体酮EP杂质F 黄体酮6-半琥珀酸酯 黄体酮 17alpha-氢过氧化物 黄体酮 11-半琥珀酸酯 黄体酮 麦角甾醇葡萄糖苷 麦角甾醇氢琥珀酸盐 麦角甾烷-6-酮,2,3-环氧-22,23-二羟基-,(2b,3b,5a,22R,23R,24S)-(9CI) 麦角甾烷-3,6,8,15,16-五唑,28-[[2-O-(2,4-二-O-甲基-b-D-吡喃木糖基)-a-L-呋喃阿拉伯糖基]氧代]-,(3b,5a,6a,15b,16b,24x)-(9CI) 麦角甾烷-26-酸,5,6:24,25-二环氧-14,17,22-三羟基-1-羰基-,d-内酯,(5b,6b,14b,17a,22R,24S,25S)-(9CI) 麦角甾-8-烯-3-醇 麦角甾-8,24(28)-二烯-26-酸,7-羟基-4-甲基-3,11-二羰基-,(4a,5a,7b,25S)- 麦角甾-7,22-二烯-3-酮 麦角甾-7,22-二烯-17-醇-3-酮 麦角甾-5,24-二烯-26-酸,3-(b-D-吡喃葡萄糖氧基)-1,22,27-三羟基-,d-内酯,(1a,3b,22R)- 麦角甾-5,22,25-三烯-3-醇 麦角甾-4,6,8(14),22-四烯-3-酮 麦角甾-1,4-二烯-3-酮,7,24-二(乙酰氧基)-17,22-环氧-16,25-二羟基-,(7a,16b,22R)-(9CI) 麦角固醇 麦冬皂苷D 麦冬皂苷D 麦冬皂苷 B